These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 27592111)

  • 1. Radiopharmaceuticals in positron emission tomography: present situation and future perspectives.
    Olivas Arroyo C
    Radiologia; 2016; 58(6):468-480. PubMed ID: 27592111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estado actual y perspectivas de la imagen molecular PET en México.
    Ávila-Rodríguez MÁ; Rivera-Bravo B; Kerik-Rotenberg NE; Vallejo E; Herranz-Carnero M; Buelna-Cano C
    Gac Med Mex; 2019; 155(4):436-444. PubMed ID: 31486800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG positron emission tomography in oncology: main indications.
    Vercher-Conejero JL; Gámez Cenzano C
    Radiologia; 2016; 58(4):303-19. PubMed ID: 27184919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Positron emission tomography: current use in internal medicine and future perspectives].
    Raynaud FR; Huglo D; Steinling M
    Rev Med Interne; 2006 Dec; 27(12):932-45. PubMed ID: 16870308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Twelve years' clinical experience in using positron emission tomography: advances and prospects].
    Granov AM; Tiutin LA; Kostenikov NA; Shtukovskiĭ OA; Mostova MI; Ryzhkova DV; Tlostanova MS; Stanzhevskiĭ AA; Balabanova AA; Panfilenko AA
    Vestn Rentgenol Radiol; 2008; (1):10-8. PubMed ID: 22187894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography for modeling pathophysiological processes in vivo.
    Hendrikse NH; Luurtsema G; van der Veldt AA; Lubberink M
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):717-25. PubMed ID: 18729023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose.
    Shiue CY; Welch MJ
    Radiol Clin North Am; 2004 Nov; 42(6):1033-53, viii. PubMed ID: 15488556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new?
    Vallabhajosula S; Solnes L; Vallabhajosula B
    Semin Nucl Med; 2011 Jul; 41(4):246-64. PubMed ID: 21624560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography applications in clinical neurology.
    Singhal T
    Semin Neurol; 2012 Sep; 32(4):421-31. PubMed ID: 23361486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experience with the use of positron emission tomography (PET) in Mexico].
    Alexánderson E; Guillermo Mendoza R; Ricalde A; Romero JL; Gómez L; Narro-Robles J
    Gac Med Mex; 2006; 142(4):291-7. PubMed ID: 17022303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Usefulness of (18)FDG PET-CT scan as a diagnostic tool of fever of unknown origin].
    García-Gómez FJ; Acevedo-Báñez I; Martínez-Castillo R; García-Gutiérrez M; Tirado-Hospital JL; Borrego-Dorado I
    Med Clin (Barc); 2015 Jul; 145(2):62-6. PubMed ID: 25500351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benign variations and incidental abnormalities of myocardial FDG uptake in the fasting state as encountered during routine oncology positron emission tomography studies.
    Fukuchi K; Ohta H; Matsumura K; Ishida Y
    Br J Radiol; 2007 Jan; 80(949):3-11. PubMed ID: 17005513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
    Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbon-11: Radiochemistry and Target-Based PET Molecular Imaging Applications in Oncology, Cardiology, and Neurology.
    Goud NS; Bhattacharya A; Joshi RK; Nagaraj C; Bharath RD; Kumar P
    J Med Chem; 2021 Feb; 64(3):1223-1259. PubMed ID: 33499603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences.
    Coenen HH; Elsinga PH; Iwata R; Kilbourn MR; Pillai MR; Rajan MG; Wagner HN; Zaknun JJ
    Nucl Med Biol; 2010 Oct; 37(7):727-40. PubMed ID: 20870148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on advances in molecular PET in urological oncology.
    Kitajima K; Yamamoto S; Fukushima K; Minamimoto R; Kamai T; Jadvar H
    Jpn J Radiol; 2016 Jul; 34(7):470-85. PubMed ID: 27222021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Positron emission tomography : from classical indications to new and future applications].
    Goldman S; El Darazi E; Mathey C; Muteganya R
    Rev Med Brux; 2018; 39(4):220-226. PubMed ID: 30320981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET/MRI: a new technology in the field of molecular imaging.
    Afaq A; Syed R; Bomanji J
    Br Med Bull; 2013; 108():159-71. PubMed ID: 24227824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography.
    Shagam JY
    Radiol Technol; 2001; 72(6):551-69; quiz 570-2. PubMed ID: 11480335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.